Regenerative Cell Therapy for Hair Growth: How the Follicle Responds

Introduction

Clinic advertisements for regenerative hair treatments tend to rely on the same phrases: “harness your body’s natural healing power,” “wake up your follicles,” “regrow hair naturally.” These lines sound reassuring, but they say very little about what actually happens inside a thinning scalp. Between the marketing copy and the miniaturized follicle lies a specific chain of biological events. That chain determines whether a treatment can help and where its limits are.

This article explains that biology before any provider or product enters the picture. The central idea is simple, and it is often lost in promotional language. Most legitimate regenerative approaches do not create new hair follicles from scratch. They send signals to follicles that are dormant but still alive.

The sections below cover what happens to a follicle in androgenetic alopecia, how the paracrine signaling cascade works, which growth factors are involved (PDGF, HGF, VEGF, and IGF-1), and why the Wnt/β-catenin pathway acts as a molecular switch for hair growth. They also cover a 2025 University of Virginia discovery about KROX20+ stem cells, which suggests that “reactivation” describes these therapies more accurately than “regeneration.”

This is a mechanism-first explainer. It does not grade every study or debate regulatory philosophy. The goal is to give readers a working understanding of the follicle so they can judge treatment claims for themselves.

What Happens to a Follicle in Androgenetic Alopecia

Androgenetic alopecia (AGA), commonly called male or female pattern hair loss, underlies roughly 90% of all hair loss cases. Because it is so common, it is the baseline condition for almost every discussion of regenerative hair therapy.

The process starts with genetics and hormones. In people with an inherited predisposition, certain scalp follicles are highly sensitive to dihydrotestosterone (DHT), a potent derivative of testosterone. Under DHT’s influence, these follicles go through miniaturization, a gradual shrinking that plays out over many growth cycles.

Each hair follicle cycles through three phases:

• Anagen: the active growth phase, which normally lasts several years on the scalp
• Catagen: a short transitional phase in which growth stops
• Telogen: a resting phase, after which the hair sheds and the cycle starts again

In AGA, the anagen phase gets shorter with each cycle. Every new hair grows in thinner, shorter, and less pigmented than the one before it. Over time, thick terminal hairs are replaced by fine, wispy hairs that resemble vellus “peach fuzz.” Eventually, many follicles stop producing visible hair at all.

The key point is that a miniaturized, dormant follicle is structurally different from a destroyed one. The follicle has shrunk and gone quiet, but in many cases its basic architecture is still there. Signaling-based regenerative therapies aim at this distinction. They are designed to influence follicles that still exist, not to rebuild ones that are gone.

Inside the Follicle: The Paracrine Signaling Cascade

A common assumption is that stem cell therapy works by injecting cells that turn into new hair. The science points elsewhere. According to the International Society of Hair Restoration Surgery (ISHRS), introduced stem cells work mainly through a paracrine effect. They release signaling molecules, mostly growth factors and cytokines, that communicate with nearby follicle cells and change their behavior. The cells act as messengers, not as building material.

Adipose-derived stem cells (ADSCs), taken from fat tissue, and mesenchymal stem cells (MSCs) from various tissue sources secrete a well-characterized set of signaling molecules. Four of them come up repeatedly in the research:

• PDGF (platelet-derived growth factor): supports cell proliferation and is linked to inducing and maintaining the anagen phase
• HGF (hepatocyte growth factor): promotes cell growth and survival in the follicle environment
• VEGF (vascular endothelial growth factor): drives angiogenesis, the formation of new blood vessels, which improves the blood supply follicles depend on
• IGF-1 (insulin-like growth factor 1): supports follicle cell proliferation and helps prolong the growth phase

Peer-reviewed literature, including a 2025 review in Stem Cell Research & Therapy, describes these secreted factors as promoting hair growth through several overlapping mechanisms: regulating the hair cycle, reducing inflammation, providing antioxidant effects, and supporting neovascularization.

These signals need a receiver. Inside each follicle, at its base, is a small cluster of specialized cells called the dermal papilla. Dermal papilla cells act as the follicle’s command center. They interpret incoming signals and coordinate the follicle’s growth activity. When regenerative therapies work, the dermal papilla is the main audience for their message.

The Wnt/β-Catenin Pathway: The Molecular Switch for Hair Growth

If the dermal papilla is the command center, the Wnt/β-catenin pathway is one of its most important switches. This signaling pathway is the common mechanistic thread connecting several regenerative modalities, including ADSC-based treatments, MSC-derived exosomes, and platelet-rich plasma (PRP).

In simple terms, when Wnt signaling is activated, a protein called β-catenin builds up inside cells and moves to the nucleus. There it switches on genes involved in follicle growth and development. In the hair follicle, this activity is closely tied to the follicle’s decision to start a new growth cycle.

Preclinical and early clinical studies have shown that exosomes derived from mesenchymal stem cells can activate dermal papilla cells through this pathway and strengthen hair-growth signals. Exosomes are tiny vesicles that cells release, carrying proteins and genetic material between them. Research on umbilical cord MSC exosomes and ADSC derivatives points to the same Wnt/β-catenin mechanism.

Downstream, activation of this pathway is associated with moving follicles from the resting telogen state back into the active anagen state. For a follicle stuck in shortened cycles or long rest, that shift is the change that matters.

This fits the paracrine framework. The Wnt/β-catenin effect is a signaling-driven switch, not the creation of new follicular tissue. The therapy does not build a follicle. It tells an existing follicle to resume work, which supports the idea of reactivation over regeneration.

The 2025 UVA Discovery: Why “Reactivation” Is the More Accurate Term

In 2025, researchers at the University of Virginia, led by Dr. Lu Q. Le, reported a finding that gave the reactivation idea new scientific support. The team identified a population of KROX20+ stem cells in the upper and middle portions of the hair follicle.

The important finding is that these dormant stem cells remain present even in bald scalp tissue. In pattern hair loss, the follicle’s growth machinery is not necessarily destroyed. The cells needed to restart growth may still be there, quiet but intact.

This has broad implications. If the biological substrate for hair growth persists in balding scalp, then pattern hair loss may, in theory, be reversible. The problem becomes one of getting existing cells to respond, not replacing what was lost.

The discovery fits with the mechanisms described above. Paracrine growth factors and Wnt/β-catenin activation are signals, and signals need targets. The dormant KROX20+ cell population gives these signals a concrete biological target. Researchers can now point to specific cells that growth-factor signaling may be acting on.

This is why terminology matters:

• “Regeneration” implies building something new where nothing existed.
• “Reactivation” describes waking up cells that are already present.

The second term is more precise and better supported by the science. It also sets more honest expectations for patients about what these therapies are trying to do.

How Different Regenerative Modalities Deliver These Signals

“Regenerative cell therapy” is an umbrella term. It covers several biologically distinct approaches, and each delivers the paracrine signal in a different way. Knowing the source of each helps patients understand what they are actually being offered.

• Platelet-rich plasma (PRP): A patient’s own blood is drawn and concentrated to increase platelets, which release growth factors including PDGF and VEGF when injected into the scalp. PRP contains no stem cells. It delivers growth factor signals directly. Of the regenerative modalities, PRP has the strongest clinical evidence base. A 2026 comprehensive review in Frontiers in Medicine reported density increases of about 10 to 30 hairs per square centimeter in randomized trials. A placebo-controlled trial published in Stem Cells Translational Medicine reported a mean increase of 33.6 hairs in the target area after three months.
• Adipose-derived stem cells (ADSCs): Cells are harvested from a patient’s fat tissue and introduced into the scalp, where they secrete PDGF, HGF, VEGF, IGF-1, and other factors. The cells act as small signal factories.
• Conditioned media and secretome products: Instead of the cells themselves, these use the fluid in which stem cells were cultured, which contains the molecules the cells secreted. Registered clinical trials, including a randomized, double-blind, vehicle-controlled study of ADSC conditioned media in male AGA, are evaluating this approach.
• MSC-derived exosomes: These deliver the vesicles cells use to communicate, aiming to activate the dermal papilla through Wnt/β-catenin. Exosomes are at an earlier stage. Preclinical studies show effects on dermal papilla cell proliferation and angiogenesis, but they still lack robust clinical validation and standardized characterization.

All four approaches attempt the same thing at the biological level: get the right signals to the follicle’s command center.

What the Biology Can and Cannot Do: Setting Realistic Expectations

The mechanism explains both the promise and the limits of these therapies. Current regenerative cell science targets follicles that are miniaturized but still present. It does not create new follicles in scalp areas where none remain.

This matters most for areas of complete follicular loss. Where follicles are truly gone, there is nothing left for growth factors or Wnt signaling to act on. In those areas, surgical transplantation, performed through Follicular Unit Extraction (FUE) or Follicular Unit Transplantation (FUT), remains the method for physically relocating viable follicular units. No investigational stem cell therapy currently matches that result.

Regenerative and signaling-based approaches are best understood as adjunctive. They can support the health and density of existing or dormant follicles, and they can complement surgery. A systematic review of PRP used alongside FUE found that adding PRP was associated with higher hair density, better follicle survival, and earlier onset of growth. The authors also noted considerable variation in PRP preparation methods, treatment protocols, and outcome measures, which is an important caveat.

Understanding this distinction is what separates an informed patient from one reacting to marketing alone. A therapy that can wake a dormant follicle cannot recreate one that no longer exists.

The Regulatory Landscape Patients Should Understand

Alongside the biology, patients should know the regulatory facts.

• As of 2026, no stem cell hair restoration treatment has received FDA approval in the United States. Every commercially offered stem cell hair therapy remains investigational under U.S. regulatory standards.
• The FDA has not approved any exosome product for any condition, including hair loss. Clinics injecting exosomes are administering an unapproved biologic.

Regulators are active in this area. Through 2025 and 2026, the FDA issued warning letters to companies including Chara Biologics and New Life Medical Services for marketing unapproved stem cell and exosome products. More letters went to clinics in Florida, California, and Texas in the first quarter of 2026. On August 14, 2026, the FDA issued a warning letter to R3 Medical Companies about unapproved umbilical cord-derived products marketed for conditions including hair rejuvenation, citing violations of current good manufacturing practice (CGMP).

Consumer protection agencies have acted as well. In January 2025, the Federal Trade Commission obtained permanent bans against the co-founders of the Stem Cell Institute of America over deceptive marketing of unproven stem cell treatments.

Professional organizations also urge caution. The American Hair Loss Association reaffirmed in 2025 that it does not endorse stem cell or exosome-based treatments offered outside legitimate clinical trials or institutional research settings.

None of this means research in the field is without value. Registered clinical trials continue to study these approaches. The point is that “investigational” and “approved” mean different things, and patients should know which category a treatment falls into.

Red Flags: Questions the Biology Should Make You Ask

A grasp of the mechanism works well as a screening tool. Patients evaluating any regenerative hair provider or product can watch for these warning signs:

1. Claims of FDA approval. No stem cell or exosome hair product is FDA-approved. Any claim otherwise should end the conversation.
2. A vague or undisclosed cell source. Patients should ask exactly where the cells come from and whether live, viable cells are present. Some products marketed as “stem cell injections” come from amniotic fluid or umbilical tissue and contain no live stem cells at all, only cellular debris or proteins that are unlikely to produce any regenerative benefit.
3. Promises to replace surgery. Any suggestion that regenerative therapy can restore hair where follicles are completely gone conflicts with the biology. Signaling needs a living target.
4. Marketing based only on testimonials. Credible providers can explain how a treatment is meant to work, including paracrine signaling, dermal papilla activation, and the Wnt/β-catenin pathway, without leaning only on before-and-after photos and branded protocol names.

A provider who welcomes these questions is usually a better sign than one who avoids them.

Where the Science Is Headed

The future of the field is increasingly organized around the reactivation concept. One example is PP405, a topical small molecule from Pelage Pharmaceuticals. It contains no cells, but it targets stem cells directly. It is designed to reactivate dormant hair follicle stem cells through a lactate/LDH metabolic pathway, effectively changing the cells’ energy metabolism to restart growth.

PP405 is considered the most advanced stem cell-targeted hair loss treatment in development, with a potential FDA approval window between 2028 and 2030. That timeline matters: candidates like this remain years away from clinical availability. Treatment decisions made today should be based on current evidence, not future possibilities.

The direction is clear, though. Together with the KROX20+ findings, research like this shows the field moving away from building new follicle structures and toward reactivating dormant cells that are already present.

Conclusion

Regenerative cell therapy for hair growth works by delivering signals. It does not regenerate follicles from nothing. The chain is consistent across modalities: secreted growth factors reach the dermal papilla, the dermal papilla activates Wnt/β-catenin signaling, and the follicle cycle shifts from rest toward active growth. All of this acts on follicles that, according to current research, retain dormant stem cell populations even after visible miniaturization.

The 2025 UVA findings support this reactivation-based view and make it a more accurate framework than vague “regeneration” language. With this background, patients can evaluate provider claims, recognize unrealistic promises, and ask better questions about any proposed treatment.

Understanding the Biology Is the First Step Toward the Right Treatment Plan

Shapiro Medical Group has focused exclusively on hair restoration since 1990. The Minneapolis practice combines surgical expertise in FUE and FUT with non-surgical regenerative and medical therapies based on the mechanisms described in this article. Dr. Ron Shapiro co-authored the textbook physicians often call the “Hair Transplant Bible,” and the practice’s physicians have lectured at more than 100 conferences in over 20 countries.

Any regenerative approach should be considered in light of a person’s specific pattern of follicle miniaturization and overall treatment plan. Some patients have mostly dormant follicles that may respond to signaling-based care. Others have areas of complete loss where surgical restoration is the appropriate tool. Many benefit from a combination. Shapiro Medical Group’s one patient per day policy means each patient’s case gets the full attention of the medical team.

Patients who want to know whether regenerative therapy, surgical restoration, or a combined approach suits their biology and goals can schedule a consultation with Shapiro Medical Group’s physician-led team. Whether local to Minnesota or traveling from abroad, patients can expect a clear, evidence-based discussion of what the follicle can do and how best to help it.